Specialty Pharmacy

Top news of the week in oncology and cancer drug development.

Most of the Ebola-related deaths in West Africa could have been prevented, experts say.

Diabetes-related outcomes significantly differ by state and insurance type.

Increased use of biosimilars could create sustainable care for multiple chronic diseases.

Top articles of the week from Specialty Pharmacy Times.

The new test service helps physicians assess patient’s responses to antiretroviral therapy for HBV.

Cancer cells learn to cope with large scale DNA changes.

Top news of the day from across the health care landscape.

Pharmacists continue to rank big in lists that highlight the profession’s value.

Specialty marketplace continues to thrive going forward.

Severe adverse events may be associated with new class of hepatitis C medications.

Methotrexate and cyclophosphamide burn excessive dietary fat.

Newly-approved nusinersen does not completely treat the muscular disorder.

Aurintricarboxylic acid blocks the spread of glioblastoma.

Top news of the day from across the health care landscape.

Large chunk of profits from prescription drug sales are going to supply chain entities and discounts.

No evidence of disease activity criteria in multiple sclerosis may need to be reconsidered.

Plant compound inhibits the metastasis of aggressive breast cancer in mice.

Combination therapy improves outcomes in cancer patients in need of an organ transplant.

High-risk family members more likely to have early subclinical manifestations of MS.

Sofosbuvir/velpatasvir/voxilaprevir granted accelerated assessment for the treatment of hepatitis C.

Markers identify patients who benefit from new and more aggressive prostate cancer treatments.

Small cell tumors respond differently to treatment.

Top news of the day from across the health care landscape.

The number of successful malpractice suits against pharmacists is low compared with dentists and physicians.

Measures to standardize specialty pharmacy data should be put in place to improve the industry.

The report validates the position of many industry experts that these fees, levied by pharmacy benefit managers and Part D plan sponsors, are ineffective and harmful.

Worldwide there are more than 350,000 HCV-related deaths per year.